nodes	percent_of_prediction	percent_of_DWPC	metapath
Mebendazole—CYP1A1—Progesterone—uterine cancer	0.262	0.363	CbGbCtD
Mebendazole—ABCB1—Progesterone—uterine cancer	0.102	0.142	CbGbCtD
Mebendazole—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0926	0.128	CbGbCtD
Mebendazole—ABCB1—Dactinomycin—uterine cancer	0.0812	0.112	CbGbCtD
Mebendazole—CYP3A4—Progesterone—uterine cancer	0.0614	0.0849	CbGbCtD
Mebendazole—ABCB1—Etoposide—uterine cancer	0.0458	0.0634	CbGbCtD
Mebendazole—ABCB1—Doxorubicin—uterine cancer	0.0313	0.0432	CbGbCtD
Mebendazole—CYP3A4—Etoposide—uterine cancer	0.0275	0.038	CbGbCtD
Mebendazole—TUBA1A—oviduct—uterine cancer	0.0219	0.134	CbGeAlD
Mebendazole—CYP3A4—Doxorubicin—uterine cancer	0.0187	0.0259	CbGbCtD
Mebendazole—TUBB4B—oviduct—uterine cancer	0.0146	0.0892	CbGeAlD
Mebendazole—TUBA1A—myometrium—uterine cancer	0.00701	0.0428	CbGeAlD
Mebendazole—TUBA1A—epithelium—uterine cancer	0.0055	0.0336	CbGeAlD
Mebendazole—TUBA1A—uterine cervix—uterine cancer	0.00546	0.0333	CbGeAlD
Mebendazole—TUBA1A—smooth muscle tissue—uterine cancer	0.0053	0.0324	CbGeAlD
Mebendazole—TUBA1A—decidua—uterine cancer	0.0052	0.0317	CbGeAlD
Mebendazole—TUBA1A—renal system—uterine cancer	0.0051	0.0312	CbGeAlD
Mebendazole—TUBA1A—endometrium—uterine cancer	0.00494	0.0301	CbGeAlD
Mebendazole—TUBA1A—mammalian vulva—uterine cancer	0.00477	0.0291	CbGeAlD
Mebendazole—TUBB4B—myometrium—uterine cancer	0.00467	0.0285	CbGeAlD
Mebendazole—TUBA1A—uterus—uterine cancer	0.00455	0.0278	CbGeAlD
Mebendazole—TUBA1A—female reproductive system—uterine cancer	0.00409	0.025	CbGeAlD
Mebendazole—TUBA1A—female gonad—uterine cancer	0.00372	0.0227	CbGeAlD
Mebendazole—TUBA1A—vagina—uterine cancer	0.0037	0.0226	CbGeAlD
Mebendazole—TUBB4B—uterine cervix—uterine cancer	0.00364	0.0222	CbGeAlD
Mebendazole—TUBB4B—smooth muscle tissue—uterine cancer	0.00353	0.0216	CbGeAlD
Mebendazole—TUBB4B—decidua—uterine cancer	0.00347	0.0211	CbGeAlD
Mebendazole—TUBB4B—renal system—uterine cancer	0.0034	0.0208	CbGeAlD
Mebendazole—TUBB4B—endometrium—uterine cancer	0.00329	0.0201	CbGeAlD
Mebendazole—CYP1A1—Benzo(a)pyrene metabolism—AKR1C1—uterine cancer	0.00323	0.0396	CbGpPWpGaD
Mebendazole—TUBB4B—mammalian vulva—uterine cancer	0.00318	0.0194	CbGeAlD
Mebendazole—Menorrhagia—Progesterone—uterine cancer	0.0031	0.101	CcSEcCtD
Mebendazole—TUBB4B—uterus—uterine cancer	0.00303	0.0185	CbGeAlD
Mebendazole—TUBA1A—p73 transcription factor network—RNF43—uterine cancer	0.003	0.0368	CbGpPWpGaD
Mebendazole—Menorrhagia—Medroxyprogesterone Acetate—uterine cancer	0.0028	0.0912	CcSEcCtD
Mebendazole—TUBB4B—female reproductive system—uterine cancer	0.00272	0.0166	CbGeAlD
Mebendazole—TUBA1A—Chaperonin-mediated protein folding—FBXW7—uterine cancer	0.00249	0.0305	CbGpPWpGaD
Mebendazole—CYP1A1—Benzo(a)pyrene metabolism—AKR1C3—uterine cancer	0.00248	0.0305	CbGpPWpGaD
Mebendazole—TUBB4B—female gonad—uterine cancer	0.00248	0.0151	CbGeAlD
Mebendazole—TUBB4B—vagina—uterine cancer	0.00246	0.015	CbGeAlD
Mebendazole—TUBA1A—lymph node—uterine cancer	0.00239	0.0146	CbGeAlD
Mebendazole—TUBA1A—Protein folding—FBXW7—uterine cancer	0.00227	0.0278	CbGpPWpGaD
Mebendazole—TUBA1A—Loss of Nlp from mitotic centrosomes—YWHAE—uterine cancer	0.00218	0.0267	CbGpPWpGaD
Mebendazole—CYP1A1—epithelium—uterine cancer	0.00205	0.0125	CbGeAlD
Mebendazole—CYP1A1—uterine cervix—uterine cancer	0.00204	0.0124	CbGeAlD
Mebendazole—TUBA1A—Centrosome maturation—YWHAE—uterine cancer	0.00193	0.0236	CbGpPWpGaD
Mebendazole—CYP1A1—renal system—uterine cancer	0.00191	0.0116	CbGeAlD
Mebendazole—TUBA1A—Parkin-Ubiquitin Proteasomal System pathway—FBXW7—uterine cancer	0.00187	0.0229	CbGpPWpGaD
Mebendazole—CYP1A1—mammalian vulva—uterine cancer	0.00178	0.0109	CbGeAlD
Mebendazole—TUBA1A—Regulation of PLK1 Activity at G2/M Transition—YWHAE—uterine cancer	0.00177	0.0217	CbGpPWpGaD
Mebendazole—CYP1A1—uterus—uterine cancer	0.0017	0.0104	CbGeAlD
Mebendazole—TUBB4B—lymph node—uterine cancer	0.00159	0.00973	CbGeAlD
Mebendazole—CYP3A4—Benzo(a)pyrene metabolism—AKR1C1—uterine cancer	0.00159	0.0195	CbGpPWpGaD
Mebendazole—CYP1A1—female reproductive system—uterine cancer	0.00153	0.00931	CbGeAlD
Mebendazole—TUBB4B—Chaperonin-mediated protein folding—FBXW7—uterine cancer	0.0015	0.0184	CbGpPWpGaD
Mebendazole—CYP3A4—renal system—uterine cancer	0.0014	0.00853	CbGeAlD
Mebendazole—CYP1A1—female gonad—uterine cancer	0.00139	0.00847	CbGeAlD
Mebendazole—CYP1A1—vagina—uterine cancer	0.00138	0.00842	CbGeAlD
Mebendazole—TUBB4B—Protein folding—FBXW7—uterine cancer	0.00137	0.0168	CbGpPWpGaD
Mebendazole—ABCB1—myometrium—uterine cancer	0.00136	0.0083	CbGeAlD
Mebendazole—TUBA1A—G2/M Transition—YWHAE—uterine cancer	0.00133	0.0163	CbGpPWpGaD
Mebendazole—TUBB4B—Loss of Nlp from mitotic centrosomes—YWHAE—uterine cancer	0.00131	0.0161	CbGpPWpGaD
Mebendazole—TUBA1A—Mitotic G2-G2/M phases—YWHAE—uterine cancer	0.00131	0.0161	CbGpPWpGaD
Mebendazole—CYP3A4—Benzo(a)pyrene metabolism—AKR1C3—uterine cancer	0.00122	0.015	CbGpPWpGaD
Mebendazole—TUBB4B—Centrosome maturation—YWHAE—uterine cancer	0.00116	0.0143	CbGpPWpGaD
Mebendazole—ABCB1—ABC-family proteins mediated transport—ABCC9—uterine cancer	0.00116	0.0142	CbGpPWpGaD
Mebendazole—TUBA1A—Pathogenic Escherichia coli infection—CDH1—uterine cancer	0.00115	0.0141	CbGpPWpGaD
Mebendazole—Hepatitis—Progesterone—uterine cancer	0.00115	0.0374	CcSEcCtD
Mebendazole—CYP1A1—Oxidative Stress—NFE2L2—uterine cancer	0.00113	0.0139	CbGpPWpGaD
Mebendazole—TUBB4B—Parkin-Ubiquitin Proteasomal System pathway—FBXW7—uterine cancer	0.00113	0.0138	CbGpPWpGaD
Mebendazole—CYP3A4—female reproductive system—uterine cancer	0.00112	0.00683	CbGeAlD
Mebendazole—TUBA1A—Metabolism of proteins—TSPYL2—uterine cancer	0.00109	0.0134	CbGpPWpGaD
Mebendazole—CYP1A1—Oxidative Stress—GPX3—uterine cancer	0.00108	0.0133	CbGpPWpGaD
Mebendazole—TUBB4B—Regulation of PLK1 Activity at G2/M Transition—YWHAE—uterine cancer	0.00107	0.0131	CbGpPWpGaD
Mebendazole—ABCB1—epithelium—uterine cancer	0.00107	0.00651	CbGeAlD
Mebendazole—ABCB1—uterine cervix—uterine cancer	0.00106	0.00646	CbGeAlD
Mebendazole—Hepatitis—Medroxyprogesterone Acetate—uterine cancer	0.00104	0.0339	CcSEcCtD
Mebendazole—ABCB1—decidua—uterine cancer	0.00101	0.00615	CbGeAlD
Mebendazole—ABCB1—renal system—uterine cancer	0.00099	0.00604	CbGeAlD
Mebendazole—CYP1A1—Estrogen Receptor Pathway—ESR1—uterine cancer	0.000963	0.0118	CbGpPWpGaD
Mebendazole—ABCB1—endometrium—uterine cancer	0.000957	0.00584	CbGeAlD
Mebendazole—Neutropenia—Dactinomycin—uterine cancer	0.00095	0.0309	CcSEcCtD
Mebendazole—TUBA1A—Cell Cycle—MLH3—uterine cancer	0.000949	0.0116	CbGpPWpGaD
Mebendazole—ABCB1—mammalian vulva—uterine cancer	0.000925	0.00565	CbGeAlD
Mebendazole—Angioedema—Progesterone—uterine cancer	0.000915	0.0298	CcSEcCtD
Mebendazole—CYP1A1—lymph node—uterine cancer	0.000893	0.00545	CbGeAlD
Mebendazole—ABCB1—uterus—uterine cancer	0.000882	0.00538	CbGeAlD
Mebendazole—Convulsion—Progesterone—uterine cancer	0.000868	0.0282	CcSEcCtD
Mebendazole—TUBA1A—Pathogenic Escherichia coli infection—CTNNB1—uterine cancer	0.000849	0.0104	CbGpPWpGaD
Mebendazole—Agranulocytosis—Dactinomycin—uterine cancer	0.000845	0.0275	CcSEcCtD
Mebendazole—Ketoprofen—CXCL8—uterine cancer	0.000839	1	CrCbGaD
Mebendazole—Angioedema—Medroxyprogesterone Acetate—uterine cancer	0.000829	0.027	CcSEcCtD
Mebendazole—Hepatitis—Dactinomycin—uterine cancer	0.000813	0.0264	CcSEcCtD
Mebendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—NFE2L2—uterine cancer	0.000805	0.00987	CbGpPWpGaD
Mebendazole—CYP1A1—Aryl Hydrocarbon Receptor—NFE2L2—uterine cancer	0.000805	0.00987	CbGpPWpGaD
Mebendazole—TUBB4B—G2/M Transition—YWHAE—uterine cancer	0.000802	0.00983	CbGpPWpGaD
Mebendazole—ABCB1—female reproductive system—uterine cancer	0.000792	0.00484	CbGeAlD
Mebendazole—TUBB4B—Mitotic G2-G2/M phases—YWHAE—uterine cancer	0.000791	0.00969	CbGpPWpGaD
Mebendazole—Convulsion—Medroxyprogesterone Acetate—uterine cancer	0.000786	0.0256	CcSEcCtD
Mebendazole—TUBA1A—Cell Cycle, Mitotic—NDC80—uterine cancer	0.000742	0.0091	CbGpPWpGaD
Mebendazole—ABCB1—female gonad—uterine cancer	0.000721	0.0044	CbGeAlD
Mebendazole—ABCB1—vagina—uterine cancer	0.000717	0.00437	CbGeAlD
Mebendazole—TUBB4B—Pathogenic Escherichia coli infection—CDH1—uterine cancer	0.000695	0.00852	CbGpPWpGaD
Mebendazole—Neutropenia—Etoposide—uterine cancer	0.000688	0.0224	CcSEcCtD
Mebendazole—Gastrointestinal pain—Progesterone—uterine cancer	0.000668	0.0217	CcSEcCtD
Mebendazole—TUBA1A—Cell Cycle—NDC80—uterine cancer	0.000664	0.00814	CbGpPWpGaD
Mebendazole—TUBB4B—Metabolism of proteins—TSPYL2—uterine cancer	0.000661	0.0081	CbGpPWpGaD
Mebendazole—Urticaria—Progesterone—uterine cancer	0.000649	0.0211	CcSEcCtD
Mebendazole—Abdominal pain—Progesterone—uterine cancer	0.000646	0.021	CcSEcCtD
Mebendazole—TUBA1A—Cell Cycle, Mitotic—POLD1—uterine cancer	0.000631	0.00774	CbGpPWpGaD
Mebendazole—CYP1A1—Arachidonic acid metabolism—AKR1C3—uterine cancer	0.00063	0.00772	CbGpPWpGaD
Mebendazole—Agranulocytosis—Etoposide—uterine cancer	0.000612	0.0199	CcSEcCtD
Mebendazole—Gastrointestinal pain—Medroxyprogesterone Acetate—uterine cancer	0.000606	0.0197	CcSEcCtD
Mebendazole—Hypersensitivity—Progesterone—uterine cancer	0.000602	0.0196	CcSEcCtD
Mebendazole—TUBA1A—p73 transcription factor network—EP300—uterine cancer	0.000591	0.00724	CbGpPWpGaD
Mebendazole—Urticaria—Medroxyprogesterone Acetate—uterine cancer	0.000588	0.0191	CcSEcCtD
Mebendazole—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	0.000586	0.019	CcSEcCtD
Mebendazole—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	0.000577	0.00707	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle—MLH3—uterine cancer	0.000573	0.00702	CbGpPWpGaD
Mebendazole—CYP1A1—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	0.000569	0.00698	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle—POLD1—uterine cancer	0.000564	0.00692	CbGpPWpGaD
Mebendazole—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.000546	0.0177	CcSEcCtD
Mebendazole—TUBA1A—Cell Cycle, Mitotic—RRM2—uterine cancer	0.000526	0.00645	CbGpPWpGaD
Mebendazole—CYP1A1—Tryptophan metabolism—CYP19A1—uterine cancer	0.000525	0.00643	CbGpPWpGaD
Mebendazole—Rash—Progesterone—uterine cancer	0.000515	0.0168	CcSEcCtD
Mebendazole—Dermatitis—Progesterone—uterine cancer	0.000515	0.0167	CcSEcCtD
Mebendazole—TUBB4B—Pathogenic Escherichia coli infection—CTNNB1—uterine cancer	0.000513	0.00629	CbGpPWpGaD
Mebendazole—TUBA1A—Metabolism of proteins—INHBA—uterine cancer	0.000489	0.00599	CbGpPWpGaD
Mebendazole—Gastrointestinal pain—Dactinomycin—uterine cancer	0.000472	0.0154	CcSEcCtD
Mebendazole—TUBA1A—Cell Cycle—RRM2—uterine cancer	0.000471	0.00577	CbGpPWpGaD
Mebendazole—CYP1A1—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	0.000468	0.00573	CbGpPWpGaD
Mebendazole—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000467	0.0152	CcSEcCtD
Mebendazole—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000467	0.0152	CcSEcCtD
Mebendazole—ABCB1—lymph node—uterine cancer	0.000464	0.00283	CbGeAlD
Mebendazole—TUBA1A—Metabolism of proteins—MME—uterine cancer	0.00046	0.00563	CbGpPWpGaD
Mebendazole—Abdominal pain—Dactinomycin—uterine cancer	0.000457	0.0148	CcSEcCtD
Mebendazole—TUBB4B—Cell Cycle, Mitotic—NDC80—uterine cancer	0.000448	0.00549	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—MAP3K4—uterine cancer	0.000445	0.00545	CbGpPWpGaD
Mebendazole—Convulsion—Etoposide—uterine cancer	0.000444	0.0144	CcSEcCtD
Mebendazole—TUBA1A—G2/M Transition—EP300—uterine cancer	0.000444	0.00544	CbGpPWpGaD
Mebendazole—CYP1A1—Metapathway biotransformation—AKR1B10—uterine cancer	0.00044	0.0054	CbGpPWpGaD
Mebendazole—TUBA1A—Mitotic G2-G2/M phases—EP300—uterine cancer	0.000438	0.00536	CbGpPWpGaD
Mebendazole—Hypersensitivity—Dactinomycin—uterine cancer	0.000426	0.0138	CcSEcCtD
Mebendazole—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	0.000424	0.0052	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle, Mitotic—YWHAE—uterine cancer	0.000423	0.00518	CbGpPWpGaD
Mebendazole—CYP1A1—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	0.000419	0.00513	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle—MLH1—uterine cancer	0.000418	0.00512	CbGpPWpGaD
Mebendazole—CYP1A1—Metapathway biotransformation—AKR1B1—uterine cancer	0.000409	0.00502	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle—NDC80—uterine cancer	0.000401	0.00491	CbGpPWpGaD
Mebendazole—TUBB4B—Transmembrane transport of small molecules—ABCC9—uterine cancer	0.000398	0.00488	CbGpPWpGaD
Mebendazole—Neutropenia—Epirubicin—uterine cancer	0.000385	0.0125	CcSEcCtD
Mebendazole—TUBB4B—Cell Cycle, Mitotic—POLD1—uterine cancer	0.000381	0.00467	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle—YWHAE—uterine cancer	0.000378	0.00463	CbGpPWpGaD
Mebendazole—Rash—Dactinomycin—uterine cancer	0.000364	0.0118	CcSEcCtD
Mebendazole—Neutropenia—Doxorubicin—uterine cancer	0.000357	0.0116	CcSEcCtD
Mebendazole—CYP1A1—Aryl Hydrocarbon Receptor—ESR1—uterine cancer	0.000351	0.0043	CbGpPWpGaD
Mebendazole—CYP1A1—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	0.000344	0.00422	CbGpPWpGaD
Mebendazole—Agranulocytosis—Epirubicin—uterine cancer	0.000343	0.0112	CcSEcCtD
Mebendazole—Gastrointestinal pain—Etoposide—uterine cancer	0.000342	0.0111	CcSEcCtD
Mebendazole—TUBB4B—Cell Cycle—POLD1—uterine cancer	0.000341	0.00418	CbGpPWpGaD
Mebendazole—Urticaria—Etoposide—uterine cancer	0.000332	0.0108	CcSEcCtD
Mebendazole—Abdominal pain—Etoposide—uterine cancer	0.000331	0.0107	CcSEcCtD
Mebendazole—Hepatitis—Epirubicin—uterine cancer	0.00033	0.0107	CcSEcCtD
Mebendazole—TUBB4B—Cell Cycle, Mitotic—RRM2—uterine cancer	0.000318	0.00389	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle, Mitotic—CDKN2B—uterine cancer	0.000317	0.00389	CbGpPWpGaD
Mebendazole—Agranulocytosis—Doxorubicin—uterine cancer	0.000317	0.0103	CcSEcCtD
Mebendazole—Hypersensitivity—Etoposide—uterine cancer	0.000308	0.01	CcSEcCtD
Mebendazole—Hepatitis—Doxorubicin—uterine cancer	0.000305	0.00993	CcSEcCtD
Mebendazole—TUBA1A—Metabolism of proteins—FBXW7—uterine cancer	0.000302	0.0037	CbGpPWpGaD
Mebendazole—CYP1A1—Metapathway biotransformation—AKR1C1—uterine cancer	0.000301	0.00368	CbGpPWpGaD
Mebendazole—TUBB4B—Metabolism of proteins—INHBA—uterine cancer	0.000295	0.00362	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle—RRM2—uterine cancer	0.000284	0.00348	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle—CDKN2B—uterine cancer	0.000284	0.00348	CbGpPWpGaD
Mebendazole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	0.000284	0.00348	CbGpPWpGaD
Mebendazole—CYP3A4—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	0.00028	0.00343	CbGpPWpGaD
Mebendazole—TUBB4B—Metabolism of proteins—MME—uterine cancer	0.000277	0.0034	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle, Mitotic—BIRC5—uterine cancer	0.000274	0.00336	CbGpPWpGaD
Mebendazole—TUBB4B—G2/M Transition—EP300—uterine cancer	0.000268	0.00328	CbGpPWpGaD
Mebendazole—TUBB4B—Mitotic G2-G2/M phases—EP300—uterine cancer	0.000264	0.00324	CbGpPWpGaD
Mebendazole—CYP1A1—Metapathway biotransformation—GPX3—uterine cancer	0.000264	0.00323	CbGpPWpGaD
Mebendazole—Rash—Etoposide—uterine cancer	0.000264	0.00857	CcSEcCtD
Mebendazole—Dermatitis—Etoposide—uterine cancer	0.000263	0.00856	CcSEcCtD
Mebendazole—CYP3A4—Tryptophan metabolism—CYP19A1—uterine cancer	0.000258	0.00317	CbGpPWpGaD
Mebendazole—ABCB1—HIF-1-alpha transcription factor network—SMAD3—uterine cancer	0.000257	0.00315	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle, Mitotic—YWHAE—uterine cancer	0.000255	0.00313	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle—MLH1—uterine cancer	0.000252	0.00309	CbGpPWpGaD
Mebendazole—Convulsion—Epirubicin—uterine cancer	0.000249	0.00809	CcSEcCtD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—INHBA—uterine cancer	0.000249	0.00305	CbGpPWpGaD
Mebendazole—CYP1A1—Biological oxidations—CYP11A1—uterine cancer	0.000248	0.00304	CbGpPWpGaD
Mebendazole—CYP1A1—Metapathway biotransformation—CYP11A1—uterine cancer	0.000245	0.003	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle—BIRC5—uterine cancer	0.000245	0.003	CbGpPWpGaD
Mebendazole—CYP1A1—Aryl Hydrocarbon Receptor—CDKN1B—uterine cancer	0.000238	0.00292	CbGpPWpGaD
Mebendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—CDKN1B—uterine cancer	0.000238	0.00292	CbGpPWpGaD
Mebendazole—CYP1A1—Metapathway biotransformation—AKR1C3—uterine cancer	0.000231	0.00284	CbGpPWpGaD
Mebendazole—Convulsion—Doxorubicin—uterine cancer	0.00023	0.00749	CcSEcCtD
Mebendazole—CYP3A4—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	0.00023	0.00282	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle—YWHAE—uterine cancer	0.000228	0.0028	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	0.00022	0.0027	CbGpPWpGaD
Mebendazole—CYP3A4—Metapathway biotransformation—AKR1B10—uterine cancer	0.000217	0.00266	CbGpPWpGaD
Mebendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EP300—uterine cancer	0.000209	0.00256	CbGpPWpGaD
Mebendazole—CYP1A1—Aryl Hydrocarbon Receptor—EP300—uterine cancer	0.000209	0.00256	CbGpPWpGaD
Mebendazole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	0.000209	0.00256	CbGpPWpGaD
Mebendazole—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	0.000206	0.00253	CbGpPWpGaD
Mebendazole—CYP3A4—Metapathway biotransformation—AKR1B1—uterine cancer	0.000201	0.00247	CbGpPWpGaD
Mebendazole—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—uterine cancer	0.000198	0.00243	CbGpPWpGaD
Mebendazole—CYP1A1—Aryl Hydrocarbon Receptor—NRAS—uterine cancer	0.000196	0.0024	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle, Mitotic—CDKN2B—uterine cancer	0.000192	0.00235	CbGpPWpGaD
Mebendazole—Gastrointestinal pain—Epirubicin—uterine cancer	0.000192	0.00623	CcSEcCtD
Mebendazole—Urticaria—Epirubicin—uterine cancer	0.000186	0.00605	CcSEcCtD
Mebendazole—Abdominal pain—Epirubicin—uterine cancer	0.000185	0.00602	CcSEcCtD
Mebendazole—CYP1A1—Biological oxidations—CYP19A1—uterine cancer	0.000183	0.00224	CbGpPWpGaD
Mebendazole—TUBB4B—Metabolism of proteins—FBXW7—uterine cancer	0.000182	0.00223	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle, Mitotic—CDKN2A—uterine cancer	0.000182	0.00222	CbGpPWpGaD
Mebendazole—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—uterine cancer	0.000181	0.00222	CbGpPWpGaD
Mebendazole—CYP1A1—Metapathway biotransformation—CYP19A1—uterine cancer	0.00018	0.00221	CbGpPWpGaD
Mebendazole—Gastrointestinal pain—Doxorubicin—uterine cancer	0.000177	0.00577	CcSEcCtD
Mebendazole—Hypersensitivity—Epirubicin—uterine cancer	0.000173	0.00561	CcSEcCtD
Mebendazole—Urticaria—Doxorubicin—uterine cancer	0.000172	0.0056	CcSEcCtD
Mebendazole—Abdominal pain—Doxorubicin—uterine cancer	0.000171	0.00557	CcSEcCtD
Mebendazole—TUBB4B—Cell Cycle—CDKN2B—uterine cancer	0.000171	0.0021	CbGpPWpGaD
Mebendazole—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	0.000169	0.00207	CbGpPWpGaD
Mebendazole—CYP1A1—Aryl Hydrocarbon Receptor—KRAS—uterine cancer	0.000168	0.00206	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle, Mitotic—BIRC5—uterine cancer	0.000165	0.00203	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle—CDKN2A—uterine cancer	0.000162	0.00199	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle, Mitotic—CDKN1B—uterine cancer	0.000161	0.00197	CbGpPWpGaD
Mebendazole—Hypersensitivity—Doxorubicin—uterine cancer	0.00016	0.0052	CcSEcCtD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—uterine cancer	0.000159	0.00195	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism of lipids and lipoproteins—STAR—uterine cancer	0.000159	0.00195	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	0.000159	0.00195	CbGpPWpGaD
Mebendazole—TUBA1A—Metabolism of proteins—CCL2—uterine cancer	0.000155	0.0019	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle—BIRC5—uterine cancer	0.000148	0.00181	CbGpPWpGaD
Mebendazole—CYP3A4—Metapathway biotransformation—AKR1C1—uterine cancer	0.000148	0.00181	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—uterine cancer	0.000148	0.00181	CbGpPWpGaD
Mebendazole—Rash—Epirubicin—uterine cancer	0.000148	0.00481	CcSEcCtD
Mebendazole—Dermatitis—Epirubicin—uterine cancer	0.000148	0.0048	CcSEcCtD
Mebendazole—TUBA1A—Cell Cycle—CDKN1B—uterine cancer	0.000144	0.00176	CbGpPWpGaD
Mebendazole—CYP1A1—Aryl Hydrocarbon Receptor—HRAS—uterine cancer	0.000143	0.00176	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle, Mitotic—EP300—uterine cancer	0.000141	0.00173	CbGpPWpGaD
Mebendazole—Rash—Doxorubicin—uterine cancer	0.000137	0.00445	CcSEcCtD
Mebendazole—Dermatitis—Doxorubicin—uterine cancer	0.000137	0.00444	CcSEcCtD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—uterine cancer	0.000134	0.00165	CbGpPWpGaD
Mebendazole—CYP3A4—Metapathway biotransformation—GPX3—uterine cancer	0.00013	0.00159	CbGpPWpGaD
Mebendazole—ABCB1—Allograft Rejection—CXCL8—uterine cancer	0.000126	0.00155	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle—EP300—uterine cancer	0.000126	0.00155	CbGpPWpGaD
Mebendazole—ABCB1—HIF-1-alpha transcription factor network—EP300—uterine cancer	0.000125	0.00153	CbGpPWpGaD
Mebendazole—TUBA1A—Metabolism of proteins—CXCL8—uterine cancer	0.000123	0.0015	CbGpPWpGaD
Mebendazole—CYP3A4—Biological oxidations—CYP11A1—uterine cancer	0.000122	0.0015	CbGpPWpGaD
Mebendazole—ABCB1—Transmembrane transport of small molecules—ABCC9—uterine cancer	0.000121	0.00148	CbGpPWpGaD
Mebendazole—CYP3A4—Metapathway biotransformation—CYP11A1—uterine cancer	0.000121	0.00148	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN2B—uterine cancer	0.00012	0.00147	CbGpPWpGaD
Mebendazole—ABCB1—HIF-1-alpha transcription factor network—VEGFA—uterine cancer	0.000119	0.00145	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	0.000117	0.00143	CbGpPWpGaD
Mebendazole—CYP3A4—Metapathway biotransformation—AKR1C3—uterine cancer	0.000114	0.0014	CbGpPWpGaD
Mebendazole—TUBA1A—Metabolism of proteins—CTNNB1—uterine cancer	0.000113	0.00139	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle, Mitotic—CDKN2A—uterine cancer	0.00011	0.00134	CbGpPWpGaD
Mebendazole—CYP1A1—PPARA activates gene expression—EP300—uterine cancer	0.000104	0.00128	CbGpPWpGaD
Mebendazole—ABCB1—Allograft Rejection—VEGFA—uterine cancer	0.000103	0.00126	CbGpPWpGaD
Mebendazole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—uterine cancer	0.000102	0.00125	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—NDUFB11—uterine cancer	9.82e-05	0.0012	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—SRD5A2—uterine cancer	9.82e-05	0.0012	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle—CDKN2A—uterine cancer	9.8e-05	0.0012	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle, Mitotic—CDKN1B—uterine cancer	9.71e-05	0.00119	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	9.54e-05	0.00117	CbGpPWpGaD
Mebendazole—TUBB4B—Metabolism of proteins—CCL2—uterine cancer	9.37e-05	0.00115	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle—TP53—uterine cancer	9.03e-05	0.00111	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	9.01e-05	0.0011	CbGpPWpGaD
Mebendazole—CYP3A4—Biological oxidations—CYP19A1—uterine cancer	8.99e-05	0.0011	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—uterine cancer	8.97e-05	0.0011	CbGpPWpGaD
Mebendazole—CYP3A4—Metapathway biotransformation—CYP19A1—uterine cancer	8.87e-05	0.00109	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle—CDKN1B—uterine cancer	8.68e-05	0.00106	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle, Mitotic—EP300—uterine cancer	8.52e-05	0.00104	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—NDUFB11—uterine cancer	7.84e-05	0.000961	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—SRD5A2—uterine cancer	7.84e-05	0.000961	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle—EP300—uterine cancer	7.62e-05	0.000934	CbGpPWpGaD
Mebendazole—ABCB1—HIF-1-alpha transcription factor network—AKT1—uterine cancer	7.57e-05	0.000927	CbGpPWpGaD
Mebendazole—TUBB4B—Metabolism of proteins—CXCL8—uterine cancer	7.41e-05	0.000908	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—AKR1B1—uterine cancer	7.1e-05	0.00087	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—STAR—uterine cancer	7.1e-05	0.00087	CbGpPWpGaD
Mebendazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—uterine cancer	7.03e-05	0.000861	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	7.02e-05	0.00086	CbGpPWpGaD
Mebendazole—TUBB4B—Metabolism of proteins—CTNNB1—uterine cancer	6.84e-05	0.000838	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	6.58e-05	0.000806	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	6.09e-05	0.000747	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	5.76e-05	0.000706	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—STAR—uterine cancer	5.67e-05	0.000695	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—AKR1B1—uterine cancer	5.67e-05	0.000695	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	5.61e-05	0.000688	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—POLD1—uterine cancer	5.57e-05	0.000683	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle—TP53—uterine cancer	5.45e-05	0.000669	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	5.35e-05	0.000656	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—AKR1C1—uterine cancer	5.21e-05	0.000639	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	5.07e-05	0.000621	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—SRD5A2—uterine cancer	4.83e-05	0.000592	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—NDUFB11—uterine cancer	4.83e-05	0.000592	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—RRM2—uterine cancer	4.64e-05	0.000569	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—DCN—uterine cancer	4.51e-05	0.000553	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—POLD1—uterine cancer	4.45e-05	0.000545	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	4.31e-05	0.000528	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—CYP11A1—uterine cancer	4.25e-05	0.000521	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—AKR1C1—uterine cancer	4.16e-05	0.00051	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—AKR1C3—uterine cancer	4.01e-05	0.000492	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	3.96e-05	0.000485	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	3.83e-05	0.000469	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—RRM2—uterine cancer	3.71e-05	0.000455	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—DCN—uterine cancer	3.6e-05	0.000441	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—AKR1B1—uterine cancer	3.49e-05	0.000428	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—STAR—uterine cancer	3.49e-05	0.000428	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—CYP11A1—uterine cancer	3.39e-05	0.000416	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	3.23e-05	0.000396	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—AKR1C3—uterine cancer	3.2e-05	0.000393	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—CYP19A1—uterine cancer	3.13e-05	0.000383	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—STK11—uterine cancer	3.13e-05	0.000383	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	2.93e-05	0.00036	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	2.8e-05	0.000343	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—POLD1—uterine cancer	2.74e-05	0.000336	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—AKR1C1—uterine cancer	2.56e-05	0.000314	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—STK11—uterine cancer	2.5e-05	0.000306	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—CYP19A1—uterine cancer	2.5e-05	0.000306	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—MTHFR—uterine cancer	2.35e-05	0.000288	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—RRM2—uterine cancer	2.29e-05	0.00028	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—DCN—uterine cancer	2.22e-05	0.000272	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—CYP11A1—uterine cancer	2.09e-05	0.000256	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	2.07e-05	0.000254	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—AKR1C3—uterine cancer	1.97e-05	0.000242	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—MTHFR—uterine cancer	1.88e-05	0.00023	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—STK11—uterine cancer	1.54e-05	0.000188	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—CYP19A1—uterine cancer	1.54e-05	0.000188	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—PTEN—uterine cancer	1.31e-05	0.00016	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—EP300—uterine cancer	1.25e-05	0.000153	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—MTHFR—uterine cancer	1.16e-05	0.000142	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—PTEN—uterine cancer	1.04e-05	0.000128	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—EP300—uterine cancer	9.95e-06	0.000122	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—PIK3CA—uterine cancer	9.22e-06	0.000113	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—AKT1—uterine cancer	7.53e-06	9.23e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—PIK3CA—uterine cancer	7.36e-06	9.02e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—PTEN—uterine cancer	6.43e-06	7.88e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—EP300—uterine cancer	6.13e-06	7.51e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—AKT1—uterine cancer	6.01e-06	7.37e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—PIK3CA—uterine cancer	4.54e-06	5.56e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—AKT1—uterine cancer	3.71e-06	4.54e-05	CbGpPWpGaD
